This trial is evaluating whether Ligelizumab will improve 3 primary outcomes and 7 secondary outcomes in patients with Urticaria. Measurement will happen over the course of Week 12.
This trial requires 428 total participants across 8 different treatment groups
This trial involves 8 different treatments. Ligelizumab is the primary treatment being studied. Participants will be divided into 5 treatment groups. Some patients will receive a placebo treatment. The treatments being tested are in Phase 3 and have had some early promising results.
"We propose that urticaria is an exaggerated release of histamine in response to various substances; this definition will allow clinicians to evaluate and treat this common condition with a straightforward, non-invasive approach.\n" - Anonymous Online Contributor
"U.T. may present with wheals, itch or other local or general symptoms; dermatological and systemic manifestations can also occur, although the dermatological or systemic presentation is more common." - Anonymous Online Contributor
"Common treatment for urticaria includes avoidance of triggers, medications, antihistamines, mast cells inhibitors and anti-allergic medications. Antihistamine is often used alone as treatment for urticaria because its efficacy could not be found in controlled trials." - Anonymous Online Contributor
"Although there are significant differences in the frequency of urticaria by ethnic origin, ethnicity, gender and by region, approximately 18 million people per year are affected with urticaria in the United States. More studies have to be carried out to collect more precise data." - Anonymous Online Contributor
"In children and young adults, hCG is used either only on occasion or for mild urticaria. As a first line treatment for hCG-induced urticaria, low doses of antihistamine may alleviate symptoms. If used for longer than 5 days, antihistamine should be tapered and reduced to low doses." - Anonymous Online Contributor
"Although no one cause for urticaria has been definitively identified, environmental causes and drug reactions have been identified and it is likely that multiple causes are involved for the majority of patients." - Anonymous Online Contributor
"In a recent study, findings suggest possible clinical application of ligelizumab for treatment of AHR or MHR, especially in patients refractory to therapy with a conventional first-line agent." - Anonymous Online Contributor
"In a recent study, findings demonstrated that the effectivity of anti-IL-13 agents, including ligelizumab, in allergic rhinitis does not outweigh the safety level in terms of adverse events. LIG has significantly lower occurrence of adverse events with a better safety profile than ARA." - Anonymous Online Contributor
"Results from a recent paper shows a low use of systemic treatment with immunomodulators, mostly used instead of corticosteroids, with the exclusion of patients on immunosuppressive treatment and patients with severe chronic urticaria. A systematic review of the current literature shows that patients treated with systemic immunosuppressive therapy are at high risk of developing serious infections." - Anonymous Online Contributor
"Treatment with ligelizumab has shown to be effective in the treatment of patients with H1-receptor-positive urticaria. The improvement in health and health-related quality of life associated with treatment may be particularly important to patients when considering the burden of urticaria." - Anonymous Online Contributor
"As the diagnosis rate for urticaria increased in the last few years, the number of patients attending a physician's office for management of urticaria has also increased. A significant proportion of these patients present with chronic urticaria. Although a minority have severe symptoms, they still require clinical assessment and an empirical treatment of chronic urticaria. Given the high risk of harm from uncontrolled trials of therapies or from an incorrect classification of patients on the basis of observational reports, clinicians need to consider clinical trials for these patients. Physicians can obtain funding for clinical trials for urticaria by contacting the ClinicalTrials.gov website." - Anonymous Online Contributor
"Ligelizumab is effective for the treatment of persistent urticaria in the majority of patients with a high response rate. One major adverse event seen was a slight increase in liver enzymes. Data from a recent study support the notion that ligelizumab is effective for the treatment of persistent urticaria, which would be of relevance to patients with autoimmune hepatitis. ClinicalTrials.gov number: NCT00279899\nquestion: Is endothelin receptor antagonism as effective as cyclosporine. A review of the literature? answer: There is no substantial evidence to support a difference between cyclosporine and endothelin receptor antagonists in treating chronic graft dysfunction." - Anonymous Online Contributor